›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Solid Tumor Profile Plus
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Genomic Testing CooperativeType:
CE Marked
Related tests:
The Solid Tumor Profile Plus test combines the analysis of DNA with targeted transcriptome sequencing (RNA) to provide a comprehensive evaluation of cancer that includes detection of single nucleotide variation, copy number variation, gene expression levels and fusions irrespective of their partner genes. This includes testing of DNA
abnormalities in 434 genes and targeted transcriptome analysis of 1408 genes. In addition, the test is designed to detect microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination repair (HRR) and homologous recombination deficiency (HRD).
Cancer:
Solid Tumor
Gene:
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), HRD (Homologous Recombination Deficiency), MET (MET proto-oncogene, receptor tyrosine kinase), MSI (Microsatellite instability), PD-L1 (Programmed death ligand 1), PD-L2 (Programmed Cell Death 1 Ligand 2)
See More ...
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), HRD (Homologous Recombination Deficiency), MET (MET proto-oncogene, receptor tyrosine kinase), MSI (Microsatellite instability), PD-L1 (Programmed death ligand 1), PD-L2 (Programmed Cell Death 1 Ligand 2), TMB (Tumor Mutational Burden)
Method:
Targeted transcriptome sequencing
